News Aurinia Pharmaceuticals Inc.

Equities

AUPH

CA05156V1022

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.91 ^USD	+0.82%		-1.60%	-45.38%

Mar. 20	ILJIN SNT Delivers a Letter to Aurinia Pharmaceuticals	CI
Mar. 07	Aurinia Pharmaceuticals Insider Sold Shares Worth $711,094, According to a Recent SEC Filing	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UPDATE, NEW AURINIA PRESENTATION DETAILS AT THE 2024 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE	Apr. 17	AQ
New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference	Apr. 16	BU
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024	Apr. 15	BU
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference	Apr. 09	BU
ILJIN SNT Delivers a Letter to Aurinia Pharmaceuticals	Mar. 20	CI
Aurinia Pharmaceuticals Insider Sold Shares Worth $711,094, According to a Recent SEC Filing	Mar. 07	MT
Aurinia Pharmaceuticals Insider Sold Shares Worth $323,372, According to a Recent SEC Filing	Mar. 07	MT
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program	Feb. 29	BU
Aurinia to Participate in Upcoming Investor Healthcare Conferences	Feb. 27	BU
HC Wainwright Cuts Price Target on Aurinia Pharmaceuticals to $13 From $15, Maintains Buy Rating	Feb. 22	MT
RBC Cuts Price Target on Aurinia Pharmaceuticals to $8 From $13, Keeps Outperform, Speculative Risk	Feb. 16	MT
Sector Update: Health Care Stocks Higher Late Afternoon	Feb. 15	MT
Sector Update: Health Care Stocks Higher Thursday Afternoon	Feb. 15	MT
Sector Update: Health Care	Feb. 15	MT
Aurinia Pharmaceuticals Q4 Loss Widens, Revenue Increases; Concludes Strategic Review -- Shares Slump	Feb. 15	MT
Transcript : Aurinia Pharmaceuticals Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Aurinia: Q4 Earnings Snapshot	Feb. 15	AQ
Aurinia Pharmaceuticals Inc. announces an Equity Buyback for $150 million worth of its shares.	Feb. 15	CI
Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q4 Revenue $45.1M, vs. Street Est of $45.2M	Feb. 15	MT
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Aurinia Pharmaceuticals Inc.

Equities

AUPH

CA05156V1022

Summary

Filters